EuroVacc successfully completes first clinical phase
Geneart GmbH located in BioPark Regensburg has in cooperation with the Institute for Medical Microbiology and Hygiene at the University of Regensburg developed the decisive gene sequence for the production of a vaccination against the immune disease HIV. The genes were integrated into a modified smallpox virus from Aventis Pasteur and tested on 24 healthy test candidates in London and Lausanne. The experiment demonstrated that in the majority of the tested people, the necessary stimulation of immune cells could be achieved, these cells located HIV cells and eliminated them. Geneart and the university are important partners in the EuroVacc project. Over the last four years, scientists and researchers from all over Europe are working together, in the date largest European research consortium, to find vaccinations for HIV, Tuberculosis and Malaria. In the HIV project, a close cooperation between the University of Regensburg, headed by Prof. Hans Wolf, and the Chinese Center for Disease Control in Beijing, has been established.
The Geneart company, which specializes in the production of synthetic genes, was able to produce the exact synthetic copy of an HIV gene. The Geneart patented genes may well be the basis for the first vaccination against HIV and are intended to be supplemented with a DNA-vaccination that was also developed in Regensburg. This combination is scheduled to be tested in London and Lausanne as well.
For more infomation see: